Ajanta Pharma disclosed on May 5, 2026, that its Nomination and Remuneration Committee of the Board of Directors convened a meeting and approved key decisions relating to its Employee Stock Option Plan (ESOP). The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

ESOP Grant Details

The committee approved the grant of stock options under the Ajanta Pharma Share Based Incentive Plan 2019. The key parameters of the grant are outlined below:

Cancellation of Stock Options

In addition to the fresh grant, the Nomination and Remuneration Committee also approved the cancellation of 850 stock options. These cancelled options have been credited back to the ESOP pool, making them available for future grants under the plan.

Regulatory Disclosure

The intimation was submitted to both BSE Limited and the National Stock Exchange of India in compliance with applicable SEBI listing regulations. The communication was signed by Gaurang Shah, Sr. VP - Legal & Company Secretary, on May 5, 2026.

Ajanta Pharma Limited has informed stock exchanges that the US FDA inspection at its manufacturing facility in Paithan, Maharashtra has concluded with the issuance of Form-483. The pharmaceutical company disclosed this development through a regulatory filing under Regulation 30 of SEBI Listing Regulations on April 22, 2026.

Inspection Details

The US FDA inspection was conducted over a period of nine days at the company's Paithan manufacturing facility. The regulatory examination covered various aspects of the manufacturing operations and compliance standards.

Regulatory Compliance

Form-483 is a standard document issued by the US FDA that lists observations made during facility inspections. The document typically highlights areas where the agency believes the company may not be in compliance with FDA regulations or good manufacturing practices.

Company Response

Ajanta Pharma has stated that it will respond to the US FDA within the stipulated timeline as required by regulatory protocols. The company's response will address each of the 5 observations noted in the Form-483 document.

Disclosure Requirements

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was signed by Gaurang Shah, Senior Vice President – Legal & Company Secretary, ensuring compliance with mandatory reporting requirements for listed companies.